Never stop hormonal endometriosis treatment without medical guidance
Funding CS was member of the Radboudumc Center of Expertise for Neuromuscular Disorders (Radboud-NMD), the Netherlands Neuromuscular Center (NL-NMD), and the European Reference Network for rare Neuromuscular Diseases (EURO-NMD)
Food and Drug Administration (2026) Related Dosing Protocols Educational and research use only Peptide Dosing Protocols is an independent educational research reference

Purified Water, Cyclohexasiloxane, Zinc Oxide, Propanediol, Lauryl Polyglyceryl-3 Polydimethylsiloxyethyl Dimethicone, Butyloctyl Salicylate, Butylene Glycol Dicaprylate/dicaprate, Niacinamide, Coco-caprylate/caprate, 1,2-hexanediol, Disteardimonium Hectorite, Neopentyl Glycol Diheptanoate, Sodium Chloride, * Sodium Hyaluronate, Ceramide Np, * Hyaluronic Acid, Hydrolyzed Sodium Hyaluronate, Hydrolyzed Hyaluronic Acid, * Sodium Acetylated Hyaluronate, * Hydroxypropyl Trimonium Hyaluronate, Polyglyceryl-3 Polydimethylsiloxyethyl Dimethicone, Sorbitan Sesquioleate, Triethoxyca Prylylsilane, Vp/acosin Copolymer, Polyglyceryl-4 Oleate, Polyhydroxystearic Acid, Hydrogenated Rapeseed Oil, Hydrogenated Palm Oil, Tocopherol, Polyglyceryl-3 Polyricinoleate, Adenosine, Butylene Glycol, Caprylic/capric Triglyceride, Phosphatidylcholine, *sodium Hyaluronate Crosspolymer, Glycine, Serine, Glutamic Acid, Lysine, Alanine, Threonine, Proline, Arginine

Safety and exploratory efficacy at 36 months in Open-HART, an open-label extension study of pridopidine in Huntingtons disease
Products have not been evaluated by Health Canada and are not intended to diagnose, treat, cure, or prevent any disease